-
Indivior, Inc. et al v. Dr. Reddy's Laboratories S.A., et al. DC CAFC
- 1:14-cv-01451
- D. Del.
- Judge: Richard G. Andrews
- Filed: 12/02/2014
- Closed: 09/05/2019
- Latest Docket Entry: 11/16/2020
- PACER
- Docket updated daily
3
Plaintiffs
2
Defendants
0
Accused
Products
5
Patents-in-Suit
1,739
Days in
Litigation
-
Indivior, Inc. et al v. Dr. Reddy's Laboratories S.A., et al. DC CAFC
- 1:14-cv-01451
- D. Del.
- Judge: Richard G. Andrews
- Filed: 12/02/2014
- Closed: 09/05/2019
- Latest Docket Entry: 11/16/2020
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A mucosally-adhesive water-soluble film product comprising: an analgesic opiate pharmaceutical active; and at least one water-soluble polymer component consisting of polyethylene oxide in combination with a hydrophilic cellulosic polymer; wherein:
view more
|
Valid (103)
Entry 205 Entry 315 Entry 313 |
4 |
The film product according to claim 1, further comprising an additional pharmaceutical active.
|
Valid (103)
Entry 205 Entry 315 Entry 313 |
5 |
The film product according to claim 1, further comprising one or more sweeteners.
|
Valid (103)
Entry 205 Entry 315 Entry 313 |
8 |
The film product according to claim 1, further comprising one or more flavors.
|
Valid (103)
Entry 205 Entry 315 Entry 313 |
9 |
The film product according to claim 1, further comprising one or more buffers.
|
Valid (103)
Entry 205 Entry 315 Entry 313 |
Claim # | Claim Text | Outcome |
---|---|---|
62 |
A drug delivery composition comprising: (i) a cast film comprising a flowable water-soluble or water swellable film-forming matrix comprising one or more substantially water soluble or water swellable polymers; and a desired amount of at least one
view more
|
Valid (103)
Entry 205 Entry 315 Entry 203 |
63 |
The drug delivery composition of claim 62, wherein the particulate active has a particle size of 150 microns or less.
|
Valid (103)
Entry 205 Entry 315 Entry 203 |
64 |
The drug delivery composition of claim 62, wherein the particulate active has a particle size of 100 microns or less.
|
Valid (103)
Entry 205 Entry 315 Entry 203 |
65 |
The drug delivery composition of claim 62, wherein said variation of drug content is less than 5% by weight per film dosage unit.
|
Valid (103)
Entry 205 Entry 315 Entry 203 |
69 |
The drug delivery composition of claim 62, wherein said taste-masking agent is present in the amount of about 0.1-30% by weight of the drug delivery composition.
|
Valid (103)
Entry 205 Entry 315 Entry 203 |
71 |
The drug delivery composition of claim 62, wherein said active is selected from the group consisting of antimicrobial agents, non-steroidal anti-inflammatory drugs, anti-tussives, decongestants, antihistamines, expectorants, anti-diarrheals, H<sub>2
view more
|
Valid (103)
Entry 205 Entry 315 Entry 203 |
73 |
The drug delivery composition of claim 62, wherein said active is an opiate or opiate derivative.
|
Valid (103)
Entry 205 Entry 315 Entry 203 |
-
Infringement
Dr. Reddy's Lab., Inc.
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Buprenorphine hydrochloride and naloxone hydrochloride sublingual filmgeneric version of Plaintiff Indivior’s Suboxone® sublingual film and ANDAGeneric version of Suboxone sublingual film | US 8,017,150 B2 |
1, 4, 5, 8, 9
|
No infringement
Entry 205Entry 315 Entry 313 |
12 mg/3 mg generic Suboxone®2 mg/0.5 mg generic Suboxone®4 mg/1 mg generic Suboxone®8 mg/2 mg generic Suboxone®Buprenorphine hydrochloride and naloxone hydrochloride sublingual filmgeneric version of Plaintiff Indivior’s Suboxone® sublingual film and ANDA | US 8,603,514 B2 |
62, 63, 64, 65, 69, 71, 73
|
No infringement
Entry 205Entry 315 Entry 203 |
12 mg/3 mg generic Suboxone®2 mg/0.5 mg generic Suboxone®4 mg/1 mg generic Suboxone®8 mg/2 mg generic Suboxone®Buprenorphine hydrochloride and naloxone hydrochloride sublingual filmgeneric version of Plaintiff Indivior’s Suboxone® sublingual film and ANDA | US 8,900,497 B2 |
24
|
No infringement
Entry 205Entry 315 Entry 203 |
Dr. Reddy's Laboratories S.A.
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Buprenorphine hydrochloride and naloxone hydrochloride sublingual filmgeneric version of Plaintiff Indivior’s Suboxone® sublingual film and ANDAGeneric version of Suboxone sublingual film | US 8,017,150 B2 |
1, 4, 5, 8, 9
|
No infringement
Entry 205Entry 315 Entry 313 |
12 mg/3 mg generic Suboxone®2 mg/0.5 mg generic Suboxone®4 mg/1 mg generic Suboxone®8 mg/2 mg generic Suboxone®Buprenorphine hydrochloride and naloxone hydrochloride sublingual filmgeneric version of Plaintiff Indivior’s Suboxone® sublingual film and ANDA | US 8,603,514 B2 |
62, 63, 64, 65, 69, 71, 73
|
No infringement
Entry 205Entry 315 Entry 203 |
12 mg/3 mg generic Suboxone®2 mg/0.5 mg generic Suboxone®4 mg/1 mg generic Suboxone®8 mg/2 mg generic Suboxone®Buprenorphine hydrochloride and naloxone hydrochloride sublingual filmgeneric version of Plaintiff Indivior’s Suboxone® sublingual film and ANDA | US 8,900,497 B2 |
24
|
No infringement
Entry 205Entry 315 Entry 203 |